A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
NCT00089830
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
Macular Degeneration
Interventions
DRUG:
MSI-1256F (Squalamine Lactate)
Sponsor
Genaera Corporation